Invest in the weight loss drug revolution and beyond
$HRTS ETF
Learn more
Filter by

GLP-1 Pioneer Prof. Jens Juul Holst Joins Tema ETFs As A Scientific Advisor

Tema ETFs (“Tema”) is pleased to announce the appointment of Prof. Jens Juul Holst, MD, DMSc, to its Scientific Advisory Board, effective immediately.

Top Biotech Deal Therapeutic Areas: Oncology, Neurology, and Cardiometabolic

According to IQVIA, if we include partnerships/collaborations, in 2023 there were 31 deals above the value of $2bn. Three major areas are emerging as...

4 Reasons why M&A is an important source of return in biotech investing

M&A is picking up in the biopharma space. Seven names owned across our life science funds, especially in oncology, have received takeover offers. In...

Investing In The Fight Against Obesity: The Case For Active ETFs

Weight-loss drugs have seen tremendous growth since the approval in mid-2021 of Wegovy (the brand name of semaglutide, also found in Ozempic, and...

Q1 2024 CIO Investor Update

Quarterly Market Commentary Markets continued their rally in Q1 2024, clocking in +10.6% for the S&P 500 and 9.0% for MSCI World. Our guiding...

Investing in biotech stocks: The case for active ETFs

While we feel the ideal approach should start with a top-down segmentation of the life sciences landscape, in our opinion a bottom-up approach to...

Investing in biotech stocks: The need for a targeted approach

Historically, investing in life sciences through public equity has resulted in a choice between broad healthcare funds or slightly narrower but still...

Investing in biotech stocks: Opportunities & challenges

We believe life sciences are an important allocation in any portfolio. Yet despite its historical outperformance of the broader market, executing an...

The Next 10 Weight-Loss Drugs: Life After Ozempic

Key Takeaways: GLP-1 drugs have pioneered obesity medication. Yet the race is on for the next generation, and we explore 10 promising new drugs in...

Generating Investment Ideas

There are 24,000 listed equities in the world that meet the minimum inclusion criteria for our ETFs1. So how do we go from that to a final portfolio?...

Immuno-oncology’s Second Act

Keytruda (Pembrolizumab) is the world’s biggest drug by sales, on track for more that $24bn in sales in 20231. The drug targets programmed cell death...

Radiopharmaceuticals: Transforming Cancer Care

Radiopharmaceuticals, or radioligand therapies, stand at the forefront of cancer treatment innovation. These therapies employ radioactive compounds...

Pursuing A Better Way To Invest In Life Sciences

We believe life sciences are an important allocation in any portfolio. Yet despite its historical outperformance of the broader market1, executing an...

Neuroscience and Mental Health: the most unmet need in life sciences

By many measures, neurological disorders remain the final frontier of life science research. Recent breakthroughs offer hope that we are at a turning...

The Next Luxury Conglomerate?

It took 30 years for Bernard Arnault to build LVMH, the conglomerate that at one point in 2023 was Europe’s most valuable company, making its founder...

Q4 2023 CIO Investor Update

Quarterly Market Commentary The calendar often marks what are somewhat arbitrary posts along an investor’s journey and the year just gone as a case...

Tema expands its life sciences fund suite with the Tema Neuroscience and Mental Health ETF (MNTL)

Tema ETFs (“Tema”) is excited to announce the launch of its Tema Neuroscience and Mental Health ETF (MNTL), on Nasdaq. MNTL is the first actively...

Cell therapies - Revolutionizing Cancer Treatment

In oncology, cell therapy is a groundbreaking approach that involves using engineered immune cells, often sourced from the patient, as a "living...

Tema's Active Investment Process

Tema’s active investment process consists of four key steps Each process step is either fundamental (human driven) and/or systematic (rules...

Artificial Intelligence (AI) and Incumbent Data Moats

Artificial intelligence in the form of natural language models burst onto the scene with the launch of Chat GPT from Open AI, which gained one...

The Next Generation of Cardiovascular Drugs

The cardiometabolic space is more than just the obesity revolution. Although GLP-1 weight loss drugs, like Wegovy, could modify cardiovascular...

Private Sector Roots to Shine Through in an Election Year

As we enter an election year in 2024, the trend that we are hearing most from firms is how reshoring is increasingly being made as an independent...

Liquid Biopsies - Revolutionizing Cancer Diagnosis

Liquid biopsies, a cutting-edge diagnostic tool, are changing the landscape of cancer detection. They harness bodily fluids, such as blood, to...

Valuation

Once we establish that the company under analysis has solid foundations and meets pillar one (operating base) and pillar two (balance sheet and cash...

2023 Rewind: 26 Key Insights from Last Year

From technological leaps to socio-economic shifts, we unwind the key highlights of this year that will define the landscape of 2024 and the years...

Security Selection

When it comes to alpha generation, one thing matters most according to Institutional Investor1 – picking the right stocks.

Tema launches its second targeted healthcare fund: the Tema Cardiovascular and Metabolic ETF (HRTS)

Tema ETFs (“Tema”) is excited to announce the launch of its actively managed Tema Cardiovascular and Metabolic ETF (HRTS), on Nasdaq. HRTS is the...

Investing in the Obesity Epidemic: The Weight Loss Drugs Revolution

Cardiovascular and metabolic diseases are a vast chronic burden on patients and society and the leading cause of death globally[1]. However, recent...

Tema's Edge

Many active managers shy away from explicitly discussing edge in their investment process. Others give convoluted or complicated answers. We firmly...

Investor's Guide to the Oncology Revolution Webinar Replay

Watch our latest webinar to learn about the exciting investment opportunities and challenges within the rapidly evolving field of cancer therapeutics...

Risk Management

If a person jumps out of a plane with a single parachute, their chances of it failing are 0.01%. If a person jumps out of a plane with two parachutes...

Tema ETFs Portfolio Construction Process

One of the surprising findings of a large academic study of 750 successful managers1 relates to portfolio construction. While this universe of...

Tema Trends: Exploring Monopoly, Luxury ETFs and Reshoring Insights

In this edition of Tema Trends we: Ask ourselves whether the rapidly evolving technology sector has the potential to create enduring...

Luxury ETF Giving US investors access to hard-to-access Luxury stocks

In the past decade, advances in technology have significantly improved individual investor’s ability to participate in the stock market. This was...

Operating Base

What does it mean to say a company has a good operating base? The concept, though not something that is used often in financial and business worlds,...

Investing in oncology: a biotech revolution in research, diagnosis, and treatment of cancer

Cancer will affect one in every two people in their lifetime. Yet, oncology is on the brink of a revolution, which we expect will trigger a material...

Tema launches actively managed oncology ETF: investing in the cancer life-science revolution

Tema ETFs (“Tema”) launches the Tema Oncology ETF (CANC), the first actively managed ETF listed in the United States seeking to provide long-term...

CIO Reflections: Q2 2023

On May 11th , 2023 , Tema launched its first three funds.

Balance Sheet and Cash Flow

Investing in the stock market can often be boiled down to understanding two seemingly simple, yet incredibly powerful, financial metrics – the...

Thematic ETFs: overcoming performance anxiety through purity of exposure

We are all being measured. Constantly. From the time we are born and the doctor wrote down our height and weight for our birth announcements, to the...

Why American Reshoring extends beyond US infrastructure

The start of this decade has been marked by impactful events which have unleashed a wave of change that is increasingly touching the American...

Introduction to thematic investing

What is thematic investing? While the formal appearance of thematic investing occurred around World War II, the practice of identifying and investing...

The risks of investing in luxury through an indexed passive vehicle

In our introduction to luxury blog, we touched on the potential limitations of investing in the luxury sector through an index approach. In this...

Monopolies: how Tema seeks to identify and invest in moat-like businesses

Many equity investors now know that quality and competitive advantage (moats1) matters. However, identifying firms that can sustain these for the...

Reshoring megatrend: how to invest in the new era of American manufacturing

Major economic undercurrents, like the development of electric power or the microprocessor, often build and come to the surface as megatrends,...

Investing in timeless elegance: the case for luxury stocks

The global luxury market is home to iconic brands and outstanding businesses. This blog explores why the luxury sector stands out by the nature of...

No results found